
Qualitative Analysis of a Stool DNA–Based Colorectal Cancer Screening Service in a Federally Qualified Health Center
PROGRAM EVALUATION BRIEF — Volume 23 — November 4, 2026
PEER REVIEWED
A flowchart describes UMMA Health’s workflow for ordering CRC screening. Each step is detailed with the health care team member performing the action and the number of patients for which it was completed. The MA notes that CRC screening is due (n = 15), creates an order (n = 15), sends the order to Exact Science (n = 15), and notifies the patient that the kit was sent (n = 13). The PCP can also see a patient in the office and assign a lab order to an MA or PN (n = 15). The PN identifies new orders (n = 15), sends them to Exact Science (n = 15), and helps notify patients that it will be shipped to their address (n = 14). Exact Science receives orders (n = 14) and ships test kits out to the home of patients (n = 13). At the end of this process, 13 of 15 patients received a testing kit, and 2 did not receive a kit or notification that a kit was sent.
Figure 1. Cologuard ordering process, qualitative analysis of a stool DNA–based colorectal cancer screening service in a federally qualified health center in Los Angeles, California, July–November 2025. Abbreviations: MA, medical assistant; PCP, primary care physician; PN, patient navigator.
A flowchart describes the patient process for completing a CRC test kit, with each step labeled with the number of patients who completed it. Once patients received their kit (n = 13), they read instructions and information (n = 13), collected and packaged a sample (n = 13), and returned the kit by mail or drop off (n = 13). After returning of the kit, patients were notified that their test result is available (n = 6) and were able to view their result (n = 5). The patients were also provided education and outreach by UMMA and Exact Sciences (n = 13), and test results were reviewed by a provider prior to release to the patient (n = 6 to 13).
Figure 2. Steps taken by patients after they receive their stool DNA–based colorectal cancer screening kit in a federally qualified health center in Los Angeles, California, July–November 2025.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.